Drug Patents Expiring in 2026
1. Abilify patent expiration
ABILIFY's oppositions filed in EPO
ABILIFY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Abilify Mycite Kit patent expiration
ABILIFY MYCITE KIT's oppositions filed in EPO
ABILIFY MYCITE KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(1 year, 4 months from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 7 months from now) | |
| US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
3. Abraxane patent
expiration
ABRAXANE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268348 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 2 months from now) | |
| US7758891 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 2 months from now) | |
| US9101543 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 2 months from now) | |
| US8034375 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(1 year, 7 months from now) | |
|
US7758891 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(1 year, 8 months from now) | |
|
US9101543 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(1 year, 8 months from now) | |
|
US8268348 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-658) | Oct 11, 2015 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| M(M-14) | Dec 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of lung cancer; Treatment of pancreatic cancer
Dosage: POWDER
How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage
ABRAXANE family patents
4. Acetadote patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8148356 | CUMBERLAND PHARMS | Acetylcysteine composition and uses therefor |
May, 2026
(1 year, 5 months from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage
ACETADOTE family patents
5. Actoplus Met Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7785627 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(1 year, 7 months from now) | |
| US7959946 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(1 year, 7 months from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ACTOPLUS MET XR before it's drug patent expiration?
More Information on Dosage
ACTOPLUS MET XR family patents
6. Adasuve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8387612 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 21, 2015 |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: NA
Dosage: POWDER
More Information on Dosage
ADASUVE family patents
7. Adempas patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7173037 | BAYER HLTHCARE | Carbamate-substituted pyrazolopyridines |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 08, 2020 |
| Orphan Drug Exclusivity(ODE-53) | Oct 08, 2020 |
Drugs and Companies using RIOCIGUAT ingredient
NCE-1 date: 08 October, 2017
Market Authorisation Date: 08 October, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage
ADEMPAS family patents
8. Advair Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Feb, 2026
(1 year, 2 months from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Aug, 2026
(1 year, 8 months from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 08 June, 2006
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
ADVAIR HFA family patents
9. Adzenys Xr-odt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8840924 | NEOS THERAPS | Compositions and methods of making rapidly dissolving ionically masked formulations |
Apr, 2026
(1 year, 3 months from now) | |
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
How can I launch a generic of ADZENYS XR-ODT before it's drug patent expiration?
More Information on Dosage
ADZENYS XR-ODT family patents
10. Afinitor patent expiration
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8410131 (Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-630) | Oct 29, 2013 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-638) | May 05, 2014 |
| New Indication(I-650) | Apr 26, 2015 |
| New Indication(I-655) | Jul 20, 2015 |
| Pediatric Exclusivity(PED) | Apr 29, 2018 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: NA
Dosage: TABLET
How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage
AFINITOR family patents
11. Afrezza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7943572 | MANNKIND | Superior control of blood glucose in diabetes treatment |
Aug, 2026
(1 year, 7 months from now) | |
| US9283193 | MANNKIND | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
Sep, 2026
(1 year, 8 months from now) | |
| US9717689 | MANNKIND | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: Pulmonary administration of an insulin composition comprising fdkp at the beginning of a meal to a patient also being treated with a long-acting insulin.
Dosage: POWDER
More Information on Dosage
AFREZZA family patents
12. Akten patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759401 | THEA PHARMA | Aqueous gel formulation and method for inducing topical anesthesia |
Jul, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 07, 2011 |
Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 October, 2008
Treatment: Method of inducing topical anesthesia in the eye
Dosage: GEL
More Information on Dosage
AKTEN family patents
13. Amondys 45 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524880 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Apr, 2026
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
| Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by inducing exon-skipping of exon 45
Dosage: SOLUTION
More Information on Dosage
AMONDYS 45 family patents
14. Ampyra patent expiration
AMPYRA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8354437 | MERZ PHARMS | Method of using sustained release aminopyridine compositions |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage
AMPYRA family patents
15. Androgel patent expiration
ANDROGEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8466137 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(1 year, 9 months from now) | |
| US8754070 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(1 year, 9 months from now) | |
| US8759329 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(1 year, 9 months from now) | |
| US8486925 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(1 year, 9 months from now) | |
| US8466136 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(1 year, 9 months from now) | |
| US8446138 | BESINS HLTHCARE | Stability compensation circuit and DC-DC converter including the same |
Oct, 2026
(1 year, 9 months from now) | |
| US8729057 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(1 year, 9 months from now) | |
| US8741881 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(1 year, 9 months from now) | |
| US8466138 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2014 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 29 April, 2011
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED; GEL
More Information on Dosage
ANDROGEL family patents
16. Aplenzin patent expiration
Can you believe APLENZIN received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7671094 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(1 year, 6 months from now) | |
| US7241805 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(1 year, 6 months from now) | |
| US7645802 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(1 year, 6 months from now) | |
| US7572935 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(1 year, 6 months from now) | |
| US7662407 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(1 year, 6 months from now) | |
| US7585897 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(1 year, 6 months from now) | |
| US7649019 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(1 year, 6 months from now) | |
| US7569610 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(1 year, 6 months from now) | |
Drugs and Companies using BUPROPION HYDROBROMIDE ingredient
Market Authorisation Date: 23 April, 2008
Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of APLENZIN before it's drug patent expiration?
More Information on Dosage
APLENZIN family patents
17. Apretude patent expiration
APRETUDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(1 year, 4 months from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 20 December, 2021
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
APRETUDE family patents
18. Aptiom patent expiration
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9206135 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9643929 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage
APTIOM family patents
19. Aricept patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8481565 | EISAI INC | Method for stabilizing anti-dementia drug |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 23, 2013 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 23 July, 2010
Treatment: NA
Dosage: TABLET
How can I launch a generic of ARICEPT before it's drug patent expiration?
More Information on Dosage
ARICEPT family patents
20. Arikayce Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679532 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(1 year, 11 months from now) | |
| US8632804 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(1 year, 11 months from now) | |
| US8642075 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults with cystic fib...
Dosage: SUSPENSION, LIPOSOMAL
More Information on Dosage
ARIKAYCE KIT family patents
21. Atelvia patent expiration
ATELVIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8246989 | APIL | Dosage forms of bisphosphonates |
Jan, 2026
(1 year, 29 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 08, 2013 |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: NA
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of ATELVIA before it's drug patent expiration?
More Information on Dosage
ATELVIA family patents
22. Atripla patent expiration
ATRIPLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9545414 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(1 year, 5 months from now) | |
| US9018192 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(1 year, 5 months from now) | |
Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 12 July, 2006
Treatment: Treatment of hiv-1 infection in adults; Treatment of hiv-1 infection in pediatric patients 12 years of age and older
Dosage: TABLET
How can I launch a generic of ATRIPLA before it's drug patent expiration?
More Information on Dosage
ATRIPLA family patents
23. Aubagio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis
Dosage: TABLET
How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage
AUBAGIO family patents
24. Auryxia patent expiration
AURYXIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8093423 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels
Dosage: TABLET
More Information on Dosage
AURYXIA family patents
25. Auvi-q patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259539 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(1 year, 1 month from now) | |
| US9278182 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(1 year, 1 month from now) | |
| US8926594 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2026
(1 year, 3 months from now) | |
| US7731686 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(1 year, 5 months from now) | |
| US10960155 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(1 year, 6 months from now) | |
| US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(1 year, 11 months from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
AUVI-Q family patents
26. Avycaz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7112592 | ABBVIE | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(1 year, 20 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ABBVIE | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-738) | Jun 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
| New Patient Population(NPP) | Dec 20, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 26 February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: Treatment of complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adult and pediatri...
Dosage: POWDER
More Information on Dosage
AVYCAZ family patents
27. Axiron patent expiration
AXIRON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180194 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(1 year, 5 months from now) | |
| US8993520 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 23, 2013 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: A method of increasing the testosterone blood level of an adult male subject in need thereof
Dosage: SOLUTION, METERED
How can I launch a generic of AXIRON before it's drug patent expiration?
More Information on Dosage
AXIRON family patents
28. Axumin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10010632 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 11 months from now) | |
| US9387266 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 11 months from now) | |
| US10953112 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Method of diagnosing tumors using positron emission tomography
Dosage: SOLUTION
More Information on Dosage
AXUMIN family patents
29. Azilect patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572834 | TEVA | Rasagiline formulations and processes for their preparation |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-685) | May 29, 2017 |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Treatment: NA
Dosage: TABLET
More Information on Dosage
AZILECT family patents
30. Baxdela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults
Dosage: POWDER; TABLET
More Information on Dosage
BAXDELA family patents
31. Beleodaq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6888027 | ACROTECH BIOPHARMA | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 03, 2021 |
| Orphan Drug Exclusivity(ODE-68) | Jul 03, 2021 |
Drugs and Companies using BELINOSTAT ingredient
NCE-1 date: 03 July, 2018
Market Authorisation Date: 03 July, 2014
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).
Dosage: POWDER
How can I launch a generic of BELEODAQ before it's drug patent expiration?
More Information on Dosage
BELEODAQ family patents
32. Belrapzo patent expiration
BELRAPZO's oppositions filed in EPO
BELRAPZO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 25 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 2018
Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma
Dosage: SOLUTION
How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage
BELRAPZO family patents
33. Bendeka patent expiration
BENDEKA's oppositions filed in EPO
BENDEKA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 25 days from now) | |
|
US8791270 (Pediatric) | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma
Dosage: SOLUTION
How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage
BENDEKA family patents
34. Bevyxxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598276 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555023 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of pulmonary embolism
Dosage: CAPSULE
More Information on Dosage
BEVYXXA family patents
35. Bosulif patent expiration
BOSULIF's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7767678 | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
Nov, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7919625 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(1 year, 5 months from now) | |
|
US7417148 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
| Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
| New Indication(I-759) | Dec 19, 2020 |
| Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
| New Indication(I-923) | Sep 26, 2026 |
| New Product(NP) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: NA
Dosage: TABLET; CAPSULE
How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage
BOSULIF family patents
36. Bridion patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44733 | MSD SUB MERCK | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
Jan, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2020 |
| M(M-262) | Jun 09, 2023 |
| M(M-291) | Jan 22, 2024 |
| New Patient Population(NPP) | Jun 25, 2024 |
Drugs and Companies using SUGAMMADEX SODIUM ingredient
NCE-1 date: 16 December, 2019
Market Authorisation Date: 15 December, 2015
Treatment: Reversal of drug-induced neuromuscular block
Dosage: SOLUTION
How can I launch a generic of BRIDION before it's drug patent expiration?
More Information on Dosage
BRIDION family patents
37. Brisdelle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8946251 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393237 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2016 |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: CAPSULE
How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage
BRISDELLE family patents
38. Briviact patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
| New Patient Population(NPP) | Aug 27, 2024 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Treatment: Treatment of partial onset seizures in patients with epilepsy aged 16 years and older with epilepsy
Dosage: TABLET; SOLUTION
How can I launch a generic of BRIVIACT before it's drug patent expiration?
More Information on Dosage
BRIVIACT family patents
39. Brixadi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236755 | BRAEBURN | Opioid depot formulations |
Jul, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2026 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 23 May, 2023
Treatment: A method of delivery of an opioid bioactive agent. a method of treatment or prophylaxis of a human or non-human animal for the treatment of opioid addiction and/or the symptoms of opioid withdrawal
Dosage: SOLUTION, EXTENDED RELEASE
More Information on Dosage
BRIXADI family patents
40. Bydureon patent expiration
BYDUREON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 3 months from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(1 year, 7 months from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 7 months from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON family patents
41. Bydureon Bcise patent expiration
BYDUREON BCISE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 3 months from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 7 months from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 7 months from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet ...
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
42. Bydureon Pen patent expiration
BYDUREON PEN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 3 months from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 7 months from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(1 year, 7 months from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON PEN family patents
43. Byvalson patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803838 | ABBVIE | Compositions comprising nebivolol |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jun 03, 2019 |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of BYVALSON before it's drug patent expiration?
More Information on Dosage
BYVALSON family patents
44. Cabenuva Kit patent expiration
CABENUVA KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(1 year, 4 months from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
45. Cabometyx patent expiration
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579473 | EXELIXIS INC | c-Met modulators and methods of use |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-760) | Dec 19, 2020 |
| New Indication(I-792) | Jan 14, 2022 |
| New Indication(I-854) | Jan 22, 2024 |
| New Indication(I-873) | Sep 17, 2024 |
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage
CABOMETYX family patents
46. Calquence patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
| New Indication(I-817) | Nov 21, 2022 |
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage
CALQUENCE family patents
47. Calquence patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
| New Indication(I-817) | Nov 21, 2022 |
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: NA
Dosage: TABLET
More Information on Dosage
CALQUENCE family patents
48. Cambia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8097651 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(1 year, 5 months from now) | |
| US7759394 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9827197 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(1 year, 5 months from now) | |
| US8927604 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 17, 2012 |
Drugs and Companies using DICLOFENAC POTASSIUM ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: FOR SOLUTION
How can I launch a generic of CAMBIA before it's drug patent expiration?
More Information on Dosage
CAMBIA family patents
49. Cerdelga patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7196205 | GENZYME CORP | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Jun, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2019 |
| Orphan Drug Exclusivity(ODE) | Aug 19, 2021 |
| Orphan Drug Exclusivity(ODE-73) | Aug 19, 2021 |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
NCE-1 date: 19 August, 2018
Market Authorisation Date: 19 August, 2014
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage
CERDELGA family patents
50. Chlorhexidine Gluconate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7427574 | SAGE PRODS | Non-woven wash cloth |
Apr, 2026
(1 year, 4 months from now) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient
Market Authorisation Date: 25 April, 2005
Treatment: NA
Dosage: CLOTH
More Information on Dosage
CHLORHEXIDINE GLUCONATE family patents
51. Clindesse patent expiration
CLINDESSE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789057 | PADAGIS US | Pharmaceutical delivery system |
Dec, 2026
(1 year, 11 months from now) | |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Method of treating bacterial vaginosis
Dosage: CREAM
How can I launch a generic of CLINDESSE before it's drug patent expiration?
More Information on Dosage
CLINDESSE family patents
52. Clorotekal patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969412 | B BRAUN MEDICAL INC | Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2020 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 September, 2017
Treatment: A method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing ...
Dosage: SOLUTION
More Information on Dosage
CLOROTEKAL family patents
53. Colazal patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(1 year, 8 months from now) | |
| US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 20, 2013 |
| Pediatric Exclusivity(PED) | Jun 20, 2014 |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE
How can I launch a generic of COLAZAL before it's drug patent expiration?
More Information on Dosage
COLAZAL family patents
54. Combivent Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage
COMBIVENT RESPIMAT family patents
55. Cometriq patent expiration
Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579473 | EXELIXIS | c-Met modulators and methods of use |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| Orphan Drug Exclusivity(ODE) | Nov 29, 2019 |
| Orphan Drug Exclusivity(ODE-33) | Nov 29, 2019 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 29 November, 2012
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
COMETRIQ family patents
56. Coreg Cr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8101209 (Pediatric) | WAYLIS THERAP | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Mar, 2026
(1 year, 2 months from now) | |
Drugs and Companies using CARVEDILOL PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2006
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of COREG CR before it's drug patent expiration?
More Information on Dosage
COREG CR family patents
57. Corlanor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 2 months from now) | |
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 2 months from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 2 months from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7361649 (Pediatric) | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(1 year, 8 months from now) | |
|
US7879842 (Pediatric) | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(1 year, 8 months from now) | |
|
US7361650 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
| Pediatric Exclusivity(PED) | Oct 22, 2026 |
| New Product(NP) | Apr 22, 2022 |
| Orphan Drug Exclusivity(ODE-234) | Apr 22, 2026 |
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
NCE-1 date: 16 October, 2019
Market Authorisation Date: 15 April, 2015
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: TABLET
How can I launch a generic of CORLANOR before it's drug patent expiration?
More Information on Dosage
CORLANOR family patents
58. Corlanor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 2 months from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 2 months from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 2 months from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
| Pediatric Exclusivity(PED) | Oct 22, 2026 |
| New Product(NP) | Apr 22, 2022 |
| Orphan Drug Exclusivity(ODE-234) | Apr 22, 2026 |
Drugs and Companies using IVABRADINE ingredient
NCE-1 date: 22 October, 2025
Market Authorisation Date: 22 April, 2019
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: SOLUTION
More Information on Dosage
CORLANOR family patents
59. Cotellic patent expiration
COTELLIC's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11597699 | GENENTECH INC | MEK inhibitors and methods of their use |
Oct, 2026
(1 year, 9 months from now) | |
| US8362002 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
| Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
| M(M-278) | Jul 28, 2025 |
| New Indication(I-902) | Oct 28, 2025 |
| Pediatric Exclusivity(PED) | Jan 28, 2026 |
| Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: As a single agent for the treatment of adult patients with histiocytic neoplasms; Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET
More Information on Dosage
COTELLIC family patents
60. Cotempla Xr-odt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8840924 | NEOS THERAPS INC | Compositions and methods of making rapidly dissolving ionically masked formulations |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2020 |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
How can I launch a generic of COTEMPLA XR-ODT before it's drug patent expiration?
More Information on Dosage
COTEMPLA XR-ODT family patents
61. Cresemba patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6812238 (Pediatric) | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
| ODE*(ODE*) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE-453) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-459) | Dec 08, 2030 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 22 November, 2022
Treatment: NA
Dosage: CAPSULE; POWDER
More Information on Dosage
CRESEMBA family patents
62. Dexilant patent expiration
DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 30 days from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 30 days from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 2 months from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(1 year, 6 months from now) | |
| US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(1 year, 7 months from now) | |
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage
DEXILANT family patents
63. Dexilant Solutab patent expiration
DEXILANT SOLUTAB's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 30 days from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 30 days from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 2 months from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(1 year, 6 months from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
More Information on Dosage
DEXILANT SOLUTAB family patents
64. Differin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8435502 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers |
Sep, 2026
(1 year, 8 months from now) | |
| US8709392 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Mar 17, 2013 |
| RTO(RTO) | Jul 08, 2019 |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of acne
Dosage: LOTION
How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage
DIFFERIN family patents
65. Duexis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8449910 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(1 year, 6 months from now) | |
| US8318202 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(1 year, 6 months from now) | |
| US8067033 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(1 year, 6 months from now) | |
| US8067451 | HORIZON | Methods and medicaments for administration of ibuprofen |
Jul, 2026
(1 year, 6 months from now) | |
| US8309127 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(1 year, 6 months from now) | |
| US8501228 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 23, 2014 |
Drugs and Companies using FAMOTIDINE; IBUPROFEN ingredient
Market Authorisation Date: 23 April, 2011
Treatment: Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications
Dosage: TABLET
How can I launch a generic of DUEXIS before it's drug patent expiration?
More Information on Dosage
DUEXIS family patents
66. Durysta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10441543 | ABBVIE | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(2 years from now) | |
| US9149428 | ABBVIE | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: NA
Dosage: IMPLANT
More Information on Dosage
DURYSTA family patents
67. Dymista patent expiration
DYMISTA's oppositions filed in EPO
DYMISTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(1 year, 2 months from now) | |
|
US8168620 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 01, 2015 |
| New Patient Population(NPP) | Feb 20, 2018 |
| Pediatric Exclusivity(PED) | Aug 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage
DYMISTA family patents
68. Elepsia Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8425938 | TRIPOINT | Pharmaceutical composition |
Feb, 2026
(1 year, 2 months from now) | |
| US8535717 | TRIPOINT | Pharmaceutical composition |
Feb, 2026
(1 year, 2 months from now) | |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 20 December, 2018
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
ELEPSIA XR family patents
69. Eliquis patent expiration
ELIQUIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6967208 | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-681) | Mar 03, 2017 |
| New Indication(I-661) | Aug 21, 2017 |
| New Indication(I-690) | Aug 21, 2017 |
| New Indication(I-691) | Aug 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
Drugs and Companies using APIXABAN ingredient
NCE-1 date: 28 December, 2016
Market Authorisation Date: 28 December, 2012
Treatment: Prophylaxis of pulmonary embolism
Dosage: TABLET
How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage
ELIQUIS family patents
70. Entresto patent expiration
ENTRESTO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9388134 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| M(M-82) | Feb 16, 2024 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: Treatment of heart failure
Dosage: TABLET
How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage
ENTRESTO family patents
71. Entresto Sprinkle patent expiration
ENTRESTO SPRINKLE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9388134 | NOVARTIS | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2026
(1 year, 10 months from now) | |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 12 April, 2024
Treatment: Treatment of heart failure
Dosage: CAPSULE, PELLETS
More Information on Dosage
ENTRESTO SPRINKLE family patents
72. Eohilia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119863 | TAKEDA PHARMS USA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(1 year, 10 months from now) | |
| US8679545 | TAKEDA PHARMS USA | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(1 year, 10 months from now) | |
| US11197822 | TAKEDA PHARMS USA | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(1 year, 10 months from now) | |
| US8497258 | TAKEDA PHARMS USA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(1 year, 10 months from now) | |
| US8975243 | TAKEDA PHARMS USA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(1 year, 10 months from now) | |
| US11413296 | TAKEDA PHARMS USA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2027 |
| Orphan Drug Exclusivity(ODE-466) | Feb 09, 2031 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 09 February, 2024
Treatment: Treatment of eosinophilic esophagitis
Dosage: SUSPENSION
More Information on Dosage
EOHILIA family patents
73. Epanova patent expiration
EPANOVA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7960370 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 05, 2019 |
Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient
NCE-1 date: 05 May, 2018
Market Authorisation Date: 05 May, 2014
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
EPANOVA family patents
74. Esbriet patent expiration
ESBRIET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7988994 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(1 year, 9 months from now) | |
| US7767225 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(1 year, 9 months from now) | |
| US8753679 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition
Dosage: CAPSULE
How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage
ESBRIET family patents
75. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9278182 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(1 year, 1 month from now) | |
| US8926594 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2026
(1 year, 3 months from now) | |
| US7731686 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(1 year, 5 months from now) | |
| US10960155 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(1 year, 6 months from now) | |
| US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(1 year, 11 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
76. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9278182 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(1 year, 1 month from now) | |
| US8926594 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2026
(1 year, 3 months from now) | |
| US7731686 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(1 year, 5 months from now) | |
| US10960155 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(1 year, 6 months from now) | |
| US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(1 year, 11 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
77. Farxiga patent expiration
FARXIGA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 3 months from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 7 months from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; Treatment of type 2 diabetes mellitus in combination with exenatide
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
78. Fetzima patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43879 | ABBVIE | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Jan, 2026
(1 year, 24 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Jul 25, 2018 |
| M(M-249) | Oct 07, 2022 |
| M(M-304) | Mar 24, 2026 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage
FETZIMA family patents
79. Fiasp Flextouch patent expiration
FIASP FLEXTOUCH's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 29, 2020 |
| New Patient Population(NPP) | Dec 19, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
FIASP FLEXTOUCH family patents
80. Flonase Sensimist Allergy Relief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8752543 | HALEON US HOLDINGS | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | |
| US8062264 | HALEON US HOLDINGS | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
FLONASE SENSIMIST ALLERGY RELIEF family patents
81. Flovent Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Feb, 2026
(1 year, 2 months from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Aug, 2026
(1 year, 8 months from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 14 May, 2004
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of FLOVENT HFA before it's drug patent expiration?
More Information on Dosage
FLOVENT HFA family patents
82. Flyrcado patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9161997 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
Feb, 2026
(1 year, 1 month from now) | |
| US7344702 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2029 |
Drugs and Companies using FLURPIRIDAZ F-18 ingredient
NCE-1 date: 27 September, 2028
Market Authorisation Date: 27 September, 2024
Treatment: Method of positron emission tomography (pet) for cardiac imaging
Dosage: SOLUTION
More Information on Dosage
FLYRCADO family patents
83. Fycompa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8772497 | CATALYST PHARMS | Method for producing 1, 2-dihydropyridine-2-one compound |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2017 |
| New Indication(I-710) | Jun 19, 2018 |
Drugs and Companies using PERAMPANEL ingredient
NCE-1 date: 22 October, 2016
Market Authorisation Date: 22 October, 2012
Treatment: NA
Dosage: TABLET; SUSPENSION
How can I launch a generic of FYCOMPA before it's drug patent expiration?
More Information on Dosage
FYCOMPA family patents
84. Gattex Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9545434 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9592274 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9592273 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9572867 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9987335 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9993528 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9555079 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US7847061 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9060992 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9545435 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9539310 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9981014 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9987334 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9968655 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9968656 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9974837 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9974835 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9968658 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
|
US9981016 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| Orphan Drug Exclusivity(ODE-37) | Dec 21, 2019 |
| Pediatric Exclusivity(PED) | Jun 21, 2020 |
| Orphan Drug Exclusivity(ODE-240) | May 16, 2026 |
Drugs and Companies using TEDUGLUTIDE ingredient
NCE-1 date: 22 June, 2019
Market Authorisation Date: 21 December, 2012
Treatment: NA
Dosage: POWDER
More Information on Dosage
GATTEX KIT family patents
85. Genosyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8057742 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan, 2026
(1 year, 1 month from now) | |
| US7618594 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2026
(1 year, 9 months from now) | |
| US7947227 | VERO BIOTECH INC | Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2026
(1 year, 9 months from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: A method of delivering nitric oxide to a patient
Dosage: GAS
More Information on Dosage
GENOSYL family patents
86. Genvoya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(1 year, 8 months from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(1 year, 10 months from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage
GENVOYA family patents
87. Giazo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192616 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(1 year, 7 months from now) | |
| US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(1 year, 8 months from now) | |
| US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 03, 2015 |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 03 February, 2012
Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients
Dosage: TABLET
How can I launch a generic of GIAZO before it's drug patent expiration?
More Information on Dosage
GIAZO family patents
88. Gilenya patent expiration
GILENYA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(1 year, 3 months from now) | |
|
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
| New Patient Population(NPP) | May 11, 2021 |
| New Strength(NS) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage
GILENYA family patents
89. Gilotrif patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43431 | BOEHRINGER INGELHEIM | Quinazoline derivatives and pharmaceutical compositions containing them |
Jan, 2026
(1 year, 26 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE43431 (Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives and pharmaceutical compositions containing them |
Jul, 2026
(1 year, 6 months from now) | |
| US9539258 | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 12, 2018 |
| New Indication(I-730) | Apr 15, 2019 |
| Orphan Drug Exclusivity(ODE-50) | Jul 12, 2020 |
| New Indication(I-763) | Jan 12, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-115) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-230) | Jan 12, 2025 |
| M(M-276) | Apr 07, 2025 |
| Pediatric Exclusivity(PED) | Oct 07, 2025 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
NCE-1 date: 07 October, 2024
Market Authorisation Date: 12 July, 2013
Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy
Dosage: TABLET
How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage
GILOTRIF family patents
90. Glyxambi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
91. Horizant patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
92. Iclusig patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9029533 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-35) | Dec 14, 2019 |
| New Indication(I-849) | Dec 18, 2023 |
| New Indication(I-934) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-472) | Mar 19, 2031 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 18 December, 2020
Treatment: A method of treating chronic myelogenous leukemia
Dosage: TABLET
How can I launch a generic of ICLUSIG before it's drug patent expiration?
More Information on Dosage
ICLUSIG family patents
93. Imbruvica patent expiration
IMBRUVICA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7514444 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US9181257 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8957079 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8735403 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8697711 | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703780 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8952015 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8497277 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8476284 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8754091 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 20 December, 2017
Treatment: Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of chronic lymphocytic leukemia; Treatment of small lymphocytic lympho...
Dosage: CAPSULE; TABLET; SUSPENSION
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
94. Inrebic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7825246 | BRISTOL-MYERS | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
INREBIC family patents
95. Isturisa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
ISTURISA family patents
96. Izervay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236773 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Nov, 2026
(1 year, 10 months from now) | |
Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient
Market Authorisation Date: 04 August, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye
Dosage: SOLUTION
More Information on Dosage
IZERVAY family patents
97. Jakafi patent expiration
JAKAFI's oppositions filed in EPO
JAKAFI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9662335 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(1 year, 11 months from now) | |
| US9814722 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
| New Indication(I-699) | Dec 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
| New Indication(I-799) | May 24, 2022 |
| New Indication(I-872) | Sep 22, 2024 |
| M(M-285) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
| Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
| Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of steroid-refractory acute graft-versus-host disease (agvhd)
Dosage: TABLET
How can I launch a generic of JAKAFI before it's drug patent expiration?
More Information on Dosage
JAKAFI family patents
98. Janumet patent expiration
JANUMET's oppositions filed in EPO
JANUMET IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET
How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage
JANUMET family patents
99. Janumet Xr patent expiration
JANUMET XR's oppositions filed in EPO
JANUMET XR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-244) | Aug 12, 2022 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
| M(M-187) | Dec 04, 2023 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JANUMET XR before it's drug patent expiration?
More Information on Dosage
JANUMET XR family patents
100. Januvia patent expiration
JANUVIA's oppositions filed in EPO
JANUVIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET
How can I launch a generic of JANUVIA before it's drug patent expiration?
More Information on Dosage
JANUVIA family patents
101. Jatenzo patent expiration
JATENZO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11179402 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Apr, 2026
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
JATENZO family patents
102. Jentadueto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-146) | Jul 30, 2017 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage
JENTADUETO family patents
103. Jentadueto Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents
104. Jevtana Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7241907 (Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
| M(M-201) | May 17, 2020 |
| M(M-209) | Sep 14, 2020 |
| Pediatric Exclusivity(PED) | Nov 17, 2020 |
| M(M-128) | Dec 18, 2023 |
Drugs and Companies using CABAZITAXEL ingredient
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage
JEVTANA KIT family patents
105. Jublia patent expiration
JUBLIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
| New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis
Dosage: SOLUTION
How can I launch a generic of JUBLIA before it's drug patent expiration?
More Information on Dosage
JUBLIA family patents
106. Juvisync patent expiration
JUVISYNC's oppositions filed in EPO
JUVISYNC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Oct, 2026
(1 year, 9 months from now) | |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 18 September, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate
Dosage: TABLET
More Information on Dosage
JUVISYNC family patents
107. Jynarque patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-779) | Apr 23, 2021 |
| Orphan Drug Exclusivity(ODE-178) | Apr 23, 2025 |
Drugs and Companies using TOLVAPTAN ingredient
Market Authorisation Date: 23 April, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of JYNARQUE before it's drug patent expiration?
More Information on Dosage
JYNARQUE family patents
108. Kaletra patent expiration
KALETRA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-124) | Apr 27, 2013 |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 09 November, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of KALETRA before it's drug patent expiration?
More Information on Dosage
KALETRA family patents
109. Kalydeco patent expiration
KALYDECO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(1 year, 6 months from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 03 May, 2023
Treatment: Method of treating cystic fibrosis; Treatment of cf in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid c...
Dosage: GRANULE
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
110. Kalydeco patent expiration
KALYDECO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8354427 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jul, 2026
(1 year, 6 months from now) | |
| US8410274 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US9670163 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 20 May, 2019
Treatment: Method of treating cystic fibrosis
Dosage: TABLET
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
111. Kerydin patent expiration
KERYDIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549938 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 1 month from now) | |
| US9566290 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 1 month from now) | |
| US9566289 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 1 month from now) | |
| US9572823 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 1 month from now) | |
|
US9549938 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(1 year, 7 months from now) | |
|
US9572823 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(1 year, 7 months from now) | |
|
US9566290 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(1 year, 7 months from now) | |
|
US9566289 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2019 |
| Pediatric Exclusivity(PED) | Jan 07, 2020 |
Drugs and Companies using TAVABOROLE ingredient
NCE-1 date: 07 January, 2019
Market Authorisation Date: 07 July, 2014
Treatment: Treatment of onychomycosis of a toenail; Treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes
Dosage: SOLUTION
How can I launch a generic of KERYDIN before it's drug patent expiration?
More Information on Dosage
KERYDIN family patents
112. Klisyri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7300931 | ALMIRALL | Compositions for treating cell proliferation disorders |
Feb, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
| New Dosing Schedule(D-192) | Jun 07, 2027 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Treatment: NA
Dosage: OINTMENT
More Information on Dosage
KLISYRI family patents
113. Koselugo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(1 year, 11 months from now) | |
| US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
Dosage: CAPSULE
More Information on Dosage
KOSELUGO family patents
114. Kuvan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7566462 (Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(1 year, 4 months from now) | |
|
US8003126 (Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2012 |
| Orphan Drug Exclusivity(ODE) | Dec 13, 2014 |
| New Patient Population(NPP) | Apr 23, 2017 |
| Pediatric Exclusivity(PED) | Oct 23, 2017 |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
NCE-1 date: 23 October, 2016
Market Authorisation Date: 13 December, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage
KUVAN family patents
115. Kyprolis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7417042 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Jul, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| New Indication(I-842) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: NA
Dosage: POWDER
How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage
KYPROLIS family patents
116. Latuda patent expiration
LATUDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(1 year, 5 months from now) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(1 year, 5 months from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(1 year, 5 months from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(1 year, 5 months from now) | |
|
US8883794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(1 year, 11 months from now) | |
|
US9907794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(1 year, 11 months from now) | |
|
US8729085 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: Treatment of schizophrenia
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
117. Lenvima patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(1 year, 9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7253286 (Pediatric) | EISAI INC | Nitrogen-containing aromatic derivatives |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-734) | May 13, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
| New Indication(I-787) | Aug 15, 2021 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-807) | Sep 17, 2022 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-14) | Apr 03, 2027 |
| Pediatric Exclusivity(PED) | Oct 03, 2027 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 03 October, 2026
Market Authorisation Date: 13 February, 2015
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage
LENVIMA family patents
118. Levemir Flextouch patent expiration
LEVEMIR FLEXTOUCH's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LEVEMIR FLEXTOUCH family patents
119. Linzess patent expiration
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
120. Livdelzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7709682 | GILEAD SCIENCES INC | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Aug 14, 2031 |
Drugs and Companies using SELADELPAR LYSINE ingredient
NCE-1 date: 14 August, 2028
Market Authorisation Date: 14 August, 2024
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
LIVDELZI family patents
121. Locoid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7378405 | BAUSCH | Stabilized steroid composition and method for its preparation |
Dec, 2026
(2 years from now) | |
Drugs and Companies using HYDROCORTISONE BUTYRATE ingredient
Market Authorisation Date: 18 May, 2007
Treatment: NA
Dosage: LOTION
How can I launch a generic of LOCOID before it's drug patent expiration?
More Information on Dosage
LOCOID family patents
122. Lonhala Magnair Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278683 | SUMITOMO PHARMA AM | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
LONHALA MAGNAIR KIT family patents
123. Lonsurf patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7799783 | TAIHO ONCOLOGY | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2020 |
| New Indication(I-794) | Feb 22, 2022 |
| Orphan Drug Exclusivity(ODE-229) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
NCE-1 date: 23 September, 2019
Market Authorisation Date: 22 September, 2015
Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if...
Dosage: TABLET
How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage
LONSURF family patents
124. Lyrica Cr patent expiration
LYRICA CR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 10 months from now) | |
| US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 10 months from now) | |
| US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2020 |
| Pediatric Exclusivity(PED) | Apr 11, 2021 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of LYRICA CR before it's drug patent expiration?
More Information on Dosage
LYRICA CR family patents
125. Makena (autoinjector) patent expiration
MAKENA (AUTOINJECTOR)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9533102 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US11446441 | COVIS | Prefilled syringe injector |
Jan, 2026
(1 year, 1 month from now) | |
| US8562564 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US9629959 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US9180259 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US8021335 | COVIS | Prefilled syringe jet injector |
Oct, 2026
(1 year, 9 months from now) | |
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Market Authorisation Date: 14 February, 2018
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of MAKENA (AUTOINJECTOR) before it's drug patent expiration?
More Information on Dosage
MAKENA (AUTOINJECTOR) family patents
126. Mavenclad patent expiration
MAVENCLAD's oppositions filed in EPO
MAVENCLAD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377903 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
May, 2026
(1 year, 5 months from now) | |
| US7713947 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1....
Dosage: TABLET
How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage
MAVENCLAD family patents
127. Mitosol patent expiration
Can you believe MITOSOL received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9205075 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jul, 2026
(1 year, 6 months from now) | |
| US8186511 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 07, 2019 |
| Orphan Drug Exclusivity(ODE-21) | Feb 07, 2019 |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 07 February, 2012
Treatment: NA
Dosage: FOR SOLUTION
More Information on Dosage
MITOSOL family patents
128. Moxatag patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8778924 | PRAGMA | Modified release amoxicillin products |
Dec, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8357394 | PRAGMA | Compositions and methods for improved efficacy of penicillin-type antibiotics |
Dec, 2026
(1 year, 11 months from now) | |
Drugs and Companies using AMOXICILLIN ingredient
Market Authorisation Date: 23 January, 2008
Treatment: Method of treating tonsillitis and/or pharyngitis secondary to streptococcus pyogenes in a once-a-day amoxicillin product
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
MOXATAG family patents
129. Mydayis patent expiration
MYDAYIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173857 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
May, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 20, 2020 |
| M(M-248) | Sep 13, 2022 |
| Pediatric Exclusivity(PED) | Mar 13, 2023 |
Market Authorisation Date: 20 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of MYDAYIS before it's drug patent expiration?
More Information on Dosage
MYDAYIS family patents
130. Naloxone Hydrochloride (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(1 year, 11 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
131. Namenda Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8283379 (Pediatric) | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(1 year, 5 months from now) | |
|
US8598233 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
|
US8168209 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
|
US8173708 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
|
US8329752 (Pediatric) | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
|
US8362085 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 21, 2013 |
| M(M-138) | Jul 03, 2017 |
| Pediatric Exclusivity(PED) | Jan 03, 2018 |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of NAMENDA XR before it's drug patent expiration?
More Information on Dosage
NAMENDA XR family patents
132. Namzaric patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8283379 (Pediatric) | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(1 year, 5 months from now) | |
|
US8173708 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
|
US8168209 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
|
US8329752 (Pediatric) | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
|
US8598233 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
|
US8362085 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(1 year, 5 months from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 July, 2016
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of NAMZARIC before it's drug patent expiration?
More Information on Dosage
NAMZARIC family patents
133. Naproxen Sodium patent expiration
NAPROXEN SODIUM's oppositions filed in EPO
NAPROXEN SODIUM IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028925 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 2 months from now) | |
| US11090280 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 2 months from now) | |
| US9693979 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 2 months from now) | |
| US9693978 | BIONPHARMA | Solvent system for enhancing the solubility of pharmaceutical agents |
Mar, 2026
(1 year, 2 months from now) | |
| US10022344 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 2 months from now) | |
Drugs and Companies using NAPROXEN SODIUM ingredient
Market Authorisation Date: 17 February, 2006
Treatment: Temporary reduction of fever
Dosage: CAPSULE
How can I launch a generic of NAPROXEN SODIUM before it's drug patent expiration?
More Information on Dosage
NAPROXEN SODIUM family patents
134. Naropin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7857802 | FRESENIUS KABI USA | Connector for medical liquid-containing packages and medical liquid-containing packages |
Nov, 2026
(1 year, 11 months from now) | |
Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 January, 2011
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of NAROPIN before it's drug patent expiration?
More Information on Dosage
NAROPIN family patents
135. Natazia patent expiration
NATAZIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071577 | BAYER HLTHCARE | Multi-phase contraceptive preparation based on a natural estrogen |
May, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 06, 2013 |
| New Indication(I-648) | Mar 14, 2015 |
Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient
Market Authorisation Date: 06 May, 2010
Treatment: Prevention of pregnancy
Dosage: TABLET
How can I launch a generic of NATAZIA before it's drug patent expiration?
More Information on Dosage
NATAZIA family patents
136. Nexplanon patent expiration
NEXPLANON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8888745 | ORGANON | Applicator for inserting an implant |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 31, 2014 |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: NA
Dosage: IMPLANT
More Information on Dosage
NEXPLANON family patents
137. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
138. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
139. Norvir patent expiration
NORVIR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-184) | Jun 07, 2024 |
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 10 February, 2010
Treatment: NA
Dosage: TABLET
How can I launch a generic of NORVIR before it's drug patent expiration?
More Information on Dosage
NORVIR family patents
140. Novolog Flextouch patent expiration
NOVOLOG FLEXTOUCH's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NOVOLOG FLEXTOUCH family patents
141. Nuedexta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7659282 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Oct 29, 2013 |
Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Treatment of pseudobulbar affect
Dosage: CAPSULE
How can I launch a generic of NUEDEXTA before it's drug patent expiration?
More Information on Dosage
NUEDEXTA family patents
142. Nuplazid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7659285 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: Treatment of parkinson's disease psychosis
Dosage: TABLET; CAPSULE
How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage
NUPLAZID family patents
143. Ofev patent expiration
OFEV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10154990 | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jan, 2026
(1 year, 21 days from now) | |
|
US6762180 (Pediatric) | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Apr, 2026
(1 year, 3 months from now) | |
|
US10154990 (Pediatric) | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Indication(I-805) | Sep 06, 2022 |
| New Indication(I-825) | Mar 09, 2023 |
| Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
| Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)
Dosage: CAPSULE
How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage
OFEV family patents
144. Olysio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8349869 | JANSSEN PRODS | Macrocylic inhibitors of hepatitis C virus |
Jul, 2026
(1 year, 7 months from now) | |
| US9856265 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(1 year, 7 months from now) | |
| US8754106 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(1 year, 7 months from now) | |
| US9040562 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(1 year, 7 months from now) | |
| US8741926 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9623022 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(1 year, 7 months from now) | |
| US9353103 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-697) | Nov 05, 2017 |
| New Dosing Schedule(D-151) | Oct 05, 2018 |
| New Indication(I-717) | Oct 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2018 |
| M(M-171) | Feb 26, 2019 |
| M(M-179) | May 20, 2019 |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
NCE-1 date: 22 November, 2017
Market Authorisation Date: 22 November, 2013
Treatment: Method of treating hepatitis c
Dosage: CAPSULE
More Information on Dosage
OLYSIO family patents
145. Omontys patent expiration
Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(1 year, 5 months from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(1 year, 5 months from now) | |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION
More Information on Dosage
OMONTYS family patents
146. Omontys Preservative Free patent expiration
Can you believe OMONTYS PRESERVATIVE FREE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(1 year, 5 months from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2017 |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION
More Information on Dosage
OMONTYS PRESERVATIVE FREE family patents
147. Ongentys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550759 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes by reducing o-methylation of l-dopa
Dosage: CAPSULE
More Information on Dosage
ONGENTYS family patents
148. Onzetra Xsail patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11571531 | CURRAX | Powder delivery devices |
Feb, 2026
(1 year, 2 months from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of drug delivery via the nasal cavity
Dosage: POWDER
More Information on Dosage
ONZETRA XSAIL family patents
149. Opsumit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 18 October, 2017
Market Authorisation Date: 18 October, 2013
Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 1% of the weight of ...
Dosage: TABLET
How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage
OPSUMIT family patents
150. Opsynvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2027 |
| Orphan Drug Exclusivity(ODE-475) | Mar 22, 2031 |
Drugs and Companies using MACITENTAN; TADALAFIL ingredient
Market Authorisation Date: 22 March, 2024
Treatment: Use of the combination of macitentan and tadalafil for the chronic treatment of adults with pulmonary arterial hypertension
Dosage: TABLET
More Information on Dosage
OPSYNVI family patents
151. Opzelura patent expiration
OPZELURA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10639310 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2026
(1 year, 11 months from now) | |
| US9974790 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(1 year, 11 months from now) | |
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 21, 2024 |
| New Indication(I-896) | Jul 18, 2025 |
| Pediatric Exclusivity(PED) | Jan 18, 2026 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription th...
Dosage: CREAM
More Information on Dosage
OPZELURA family patents
152. Orenitram patent expiration
ORENITRAM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7417070 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2026
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393203 | UNITED THERAP | Osmotic drug delivery system |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
| New Indication(I-820) | Oct 18, 2022 |
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage
ORENITRAM family patents
153. Orkambi patent expiration
ORKAMBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9216969 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(1 year, 10 months from now) | |
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7973038 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(1 year, 10 months from now) | |
| US8741933 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(1 year, 10 months from now) | |
| US9216969 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(1 year, 10 months from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 02, 2025 |
| Pediatric Exclusivity(PED) | Jan 02, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
| M(M-218) | Jan 25, 2021 |
| New Product(NP) | Aug 07, 2021 |
| Orphan Drug Exclusivity(ODE-93) | Jul 02, 2022 |
| Orphan Drug Exclusivity(ODE) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-123) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-195) | Aug 07, 2025 |
| New Strength(NS) | Sep 02, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Jan 02, 2028 |
| Orphan Drug Exclusivity(ODE-408) | Sep 02, 2029 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
NCE-1 date: 03 July, 2019
Market Authorisation Date: 02 September, 2022
Treatment: Method of treating cystic fibrosis using n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide and 3-(6-(1-2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyrid...
Dosage: GRANULE; TABLET
More Information on Dosage
ORKAMBI family patents
154. Orserdu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7612114 | STEMLINE THERAP | Selective estrogen receptor modulator |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer
Dosage: TABLET
More Information on Dosage
ORSERDU family patents
155. Osphena patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236861 | DUCHESNAY | Method for enhancing the bioavailablity of ospemifene |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
| New Indication(I-793) | Jan 25, 2022 |
Drugs and Companies using OSPEMIFENE ingredient
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Treatment: Treatment of dyspareunia associated with menopause
Dosage: TABLET
How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage
OSPHENA family patents
156. Otrexup patent expiration
OTREXUP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9533102 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US8562564 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US9629959 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US11446441 | OTTER PHARMS | Prefilled syringe injector |
Jan, 2026
(1 year, 1 month from now) | |
| US8021335 | OTTER PHARMS | Prefilled syringe jet injector |
Oct, 2026
(1 year, 9 months from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 07 November, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
OTREXUP family patents
157. Ovide patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7977324 | TARO | Process for preparing malathion for pharmaceutical use |
Aug, 2026
(1 year, 7 months from now) | |
Drugs and Companies using MALATHION ingredient
Market Authorisation Date: 02 August, 1982
Treatment: NA
Dosage: LOTION
How can I launch a generic of OVIDE before it's drug patent expiration?
More Information on Dosage
OVIDE family patents
158. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage
OZEMPIC family patents
159. Perseris Kit patent expiration
PERSERIS KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406160 | INDIVIOR | Sustained release small molecule drug formulation |
Jun, 2026
(1 year, 6 months from now) | |
| US9597402 | INDIVIOR | Sustained release small molecule drug formulation |
Sep, 2026
(1 year, 9 months from now) | |
| US10058554 | INDIVIOR | Sustained release small molecule drug formulation |
Sep, 2026
(1 year, 9 months from now) | |
| US11110093 | INDIVIOR | Sustained release small molecule drug formulation |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2021 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 27 July, 2018
Treatment: Method of treating schizophrenia; Administration of risperidone; Treating schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
PERSERIS KIT family patents
160. Picato patent expiration
PICATO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8716271 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US8735375 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US8536163 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US8377919 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US9820959 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US8372828 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US9833429 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US9861603 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US9833428 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| US8372827 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2017 |
| M(M-169) | Nov 19, 2018 |
Drugs and Companies using INGENOL MEBUTATE ingredient
NCE-1 date: 24 January, 2016
Market Authorisation Date: 23 January, 2012
Treatment: Use of ingenol mebutate to treat actinic keratosis
Dosage: GEL
How can I launch a generic of PICATO before it's drug patent expiration?
More Information on Dosage
PICATO family patents
161. Pradaxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
| New Indication(I-682) | Apr 04, 2017 |
| New Indication(I-683) | Apr 04, 2017 |
| M(M-168) | Nov 20, 2018 |
| New Strength(NS) | Nov 20, 2018 |
| New Indication(I-862) | Jun 21, 2024 |
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
Market Authorisation Date: 21 June, 2021
Treatment: NA
Dosage: PELLETS; CAPSULE
How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage
PRADAXA family patents
162. Prezcobix patent expiration
PREZCOBIX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of PREZCOBIX before it's drug patent expiration?
More Information on Dosage
PREZCOBIX family patents
163. Prezista patent expiration
PREZISTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-118) | Oct 21, 2011 |
| New Indication(I-578) | Oct 21, 2011 |
| New Dosing Schedule(D-119) | Dec 18, 2011 |
| New Strength(NS) | Dec 18, 2011 |
| New Dosing Schedule(D-129) | Dec 13, 2013 |
| Pediatric Exclusivity(PED) | Aug 01, 2016 |
| New Dosage Form(NDF) | Dec 16, 2014 |
| New Patient Population(NPP) | Dec 16, 2014 |
| New Dosing Schedule(D-135) | Feb 01, 2016 |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 16 December, 2011
Treatment: NA
Dosage: SUSPENSION; TABLET
How can I launch a generic of PREZISTA before it's drug patent expiration?
More Information on Dosage
PREZISTA family patents
164. Primatene Mist patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8367734 | ARMSTRONG PHARMS | Stable epinephrine suspension formulation with high inhalation delivery efficiency |
Jan, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 07, 2021 |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 07 November, 2018
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
PRIMATENE MIST family patents
165. Promacta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(1 year, 26 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Indication(I-664) | Nov 16, 2015 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of PROMACTA before it's drug patent expiration?
More Information on Dosage
PROMACTA family patents
166. Promacta Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(1 year, 26 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE) | Aug 26, 2021 |
| Orphan Drug Exclusivity(ODE-74) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| ODE*(ODE*) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 27 September, 2018
Treatment: NA
Dosage: FOR SUSPENSION
How can I launch a generic of PROMACTA KIT before it's drug patent expiration?
More Information on Dosage
PROMACTA KIT family patents
167. Protonix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(1 year, 5 months from now) | |
|
US7544370 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-614) | Nov 12, 2012 |
| M(M-54) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 14 November, 2007
Treatment: NA
Dosage: FOR SUSPENSION, DELAYED RELEASE
How can I launch a generic of PROTONIX before it's drug patent expiration?
More Information on Dosage
PROTONIX family patents
168. Recorlev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098877 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(1 year, 23 days from now) | |
| US9918984 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(1 year, 23 days from now) | |
| US11478471 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(1 year, 23 days from now) | |
| US10835530 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(1 year, 23 days from now) | |
| US10517868 | STRONGBRIDGE | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Jan, 2026
(1 year, 23 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-385) | Dec 30, 2028 |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative
Dosage: TABLET
More Information on Dosage
RECORLEV family patents
169. Rexulti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7888362 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618109 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 3 months from now) | |
| US8349840 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 3 months from now) | |
| US9839637 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 3 months from now) | |
|
US7888362 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(1 year, 9 months from now) | |
|
US9839637 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(1 year, 9 months from now) | |
|
US8618109 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(1 year, 9 months from now) | |
|
US8349840 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| Pediatric Exclusivity(PED) | Nov 10, 2026 |
| M(M-14) | May 08, 2027 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 10 November, 2025
Market Authorisation Date: 10 July, 2015
Treatment: Treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia
Dosage: TABLET
How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage
REXULTI family patents
170. Rezdiffra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452882 | MADRIGAL | Thyroid hormone analogs |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
REZDIFFRA family patents
171. Rhopressa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8450344 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| US9096569 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10532993 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| US11021456 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| US10882840 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS
How can I launch a generic of RHOPRESSA before it's drug patent expiration?
More Information on Dosage
RHOPRESSA family patents
172. Rocklatan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9096569 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| US8450344 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021456 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| US10532993 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| US10882840 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Mar 12, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 12 March, 2019
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS
How can I launch a generic of ROCKLATAN before it's drug patent expiration?
More Information on Dosage
ROCKLATAN family patents
173. Rybelsus patent expiration
RYBELSUS's oppositions filed in EPO
RYBELSUS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
More Information on Dosage
RYBELSUS family patents
174. Ryzodeg 70/30 patent expiration
RYZODEG 70/30's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RYZODEG 70/30 family patents
175. Samsca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 19, 2014 |
Drugs and Companies using TOLVAPTAN ingredient
NCE-1 date: 19 May, 2013
Market Authorisation Date: 19 May, 2009
Treatment: NA
Dosage: TABLET
How can I launch a generic of SAMSCA before it's drug patent expiration?
More Information on Dosage
SAMSCA family patents
176. Saphris patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(1 year, 3 months from now) | |
| US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8022228 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(1 year, 9 months from now) | |
|
US7741358 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-628) | Sep 03, 2013 |
| New Indication(I-629) | Sep 03, 2013 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2014 |
| M(M-158) | Mar 12, 2018 |
| New Patient Population(NPP) | Mar 12, 2018 |
| Pediatric Exclusivity(PED) | Sep 12, 2018 |
| New Dosing Schedule(D-166) | Jan 13, 2020 |
| New Indication(I-597) | Jan 13, 2020 |
Drugs and Companies using ASENAPINE MALEATE ingredient
NCE-1 date: 12 September, 2017
Market Authorisation Date: 12 March, 2015
Treatment: Method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients
Dosage: TABLET
How can I launch a generic of SAPHRIS before it's drug patent expiration?
More Information on Dosage
SAPHRIS family patents
177. Saxenda patent expiration
SAXENDA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
|
US8114833 (Pediatric) | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(1 year, 1 month from now) | |
|
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(1 year, 4 months from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
|
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(1 year, 7 months from now) | |
|
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(1 year, 7 months from now) | |
|
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(1 year, 7 months from now) | |
| US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
| New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage
SAXENDA family patents
178. Sensipar patent expiration
SENSIPAR's oppositions filed in EPO
SENSIPAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9375405 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(1 year, 9 months from now) | |
| US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-634) | Feb 25, 2014 |
| M(M-101) | Feb 25, 2014 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2018 |
| Orphan Drug Exclusivity(ODE-8) | Feb 25, 2018 |
| M(M-200) | May 23, 2020 |
| Orphan Drug Exclusivity(ODE-78) | Nov 21, 2021 |
Drugs and Companies using CINACALCET HYDROCHLORIDE ingredient
Market Authorisation Date: 08 March, 2004
Treatment: Method of treating hyperparathyroidism; Method of treating hypercalcemia
Dosage: TABLET
How can I launch a generic of SENSIPAR before it's drug patent expiration?
More Information on Dosage
SENSIPAR family patents
179. Signifor patent expiration
Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-34) | Dec 14, 2019 |
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 14 December, 2012
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SIGNIFOR family patents
180. Signifor Lar Kit patent expiration
Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7759308 | RECORDATI RARE | Microparticles comprising somatostatin analogues |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| New Product(NP) | Dec 15, 2017 |
| New Indication(I-785) | Jun 29, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 15, 2021 |
| Orphan Drug Exclusivity(ODE-81) | Dec 15, 2021 |
| Orphan Drug Exclusivity(ODE-268) | Jun 29, 2025 |
Drugs and Companies using PASIREOTIDE PAMOATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 29 June, 2018
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
SIGNIFOR LAR KIT family patents
181. Sinuva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585681 | INTERSECT ENT INC | Device and methods for treating paranasal sinus conditions |
Apr, 2026
(1 year, 3 months from now) | |
| US7544192 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 08, 2020 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant
Dosage: IMPLANT
More Information on Dosage
SINUVA family patents
182. Sirturo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498343 | JANSSEN THERAP | Mycobacterial inhibitors |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 28, 2019 |
| Orphan Drug Exclusivity(ODE-38) | Dec 28, 2019 |
| New Patient Population(NPP) | Aug 09, 2022 |
| Orphan Drug Exclusivity(ODE-251) | Aug 09, 2026 |
| Orphan Drug Exclusivity(ODE-307) | May 27, 2027 |
| M(M-306) | Jun 21, 2027 |
Drugs and Companies using BEDAQUILINE FUMARATE ingredient
NCE-1 date: 28 December, 2016
Market Authorisation Date: 27 May, 2020
Treatment: Treatment of pulmonary multi-drug resistant tuberculosis
Dosage: TABLET
More Information on Dosage
SIRTURO family patents
183. Skelaxin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7122566 | KING PHARMS | Metaxalone products, method of manufacture, and method of use |
Feb, 2026
(1 year, 1 month from now) | |
Drugs and Companies using METAXALONE ingredient
Market Authorisation Date: 01 January, 1982
Treatment: Treatment of musculoskeletal conditions
Dosage: TABLET
How can I launch a generic of SKELAXIN before it's drug patent expiration?
More Information on Dosage
SKELAXIN family patents
184. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628759 | BOTANIX SB | Soft anticholinergic esters |
Nov, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
185. Sorilux patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8269128 | MAYNE PHARMA | Vacuum switch tube |
May, 2026
(1 year, 5 months from now) | |
| US8629128 | MAYNE PHARMA | Vitamin formulation |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 06, 2013 |
| New Indication(I-657) | Sep 27, 2015 |
| New Patient Population(NPP) | Nov 05, 2022 |
Drugs and Companies using CALCIPOTRIENE ingredient
Market Authorisation Date: 06 October, 2010
Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older
Dosage: AEROSOL, FOAM
More Information on Dosage
SORILUX family patents
186. Spiriva patent expiration
SPIRIVA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8022082 | BOEHRINGER INGELHEIM | Method for the administration of an anticholinergic by inhalation |
Jan, 2026
(1 year, 1 month from now) | |
|
US8022082 (Pediatric) | BOEHRINGER INGELHEIM | Method for the administration of an anticholinergic by inhalation |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-89) | Dec 17, 2012 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 30 January, 2004
Treatment: Administration of an inhalable powder comprising tiotropium via device
Dosage: POWDER
How can I launch a generic of SPIRIVA before it's drug patent expiration?
More Information on Dosage
SPIRIVA family patents
187. Spiriva Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 15, 2018 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage
SPIRIVA RESPIMAT family patents
188. Sprycel patent expiration
SPRYCEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7491725 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Mar, 2026
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7491725 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Sep, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-120) | May 21, 2012 |
| Orphan Drug Exclusivity(ODE) | Jun 28, 2013 |
| M(M-94) | Oct 28, 2013 |
| New Patient Population(NPP) | Nov 09, 2020 |
| New Indication(I-791) | Dec 21, 2021 |
| Orphan Drug Exclusivity(ODE-164) | Nov 09, 2024 |
| Orphan Drug Exclusivity(ODE-225) | Dec 21, 2025 |
| Pediatric Exclusivity(PED) | Jun 21, 2026 |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 28 June, 2006
Treatment: NA
Dosage: TABLET
How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage
SPRYCEL family patents
189. Steglujan patent expiration
STEGLUJAN's oppositions filed in EPO
STEGLUJAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
| M(M-275) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
More Information on Dosage
STEGLUJAN family patents
190. Stiolto Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 21, 2018 |
| M(M-173) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
| M(M-233) | Oct 05, 2021 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 21 May, 2015
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
STIOLTO RESPIMAT family patents
191. Stribild patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(1 year, 8 months from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(1 year, 10 months from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 27, 2015 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Indication(I-704) | Dec 17, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of STRIBILD before it's drug patent expiration?
More Information on Dosage
STRIBILD family patents
192. Striverdi Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema
Dosage: SPRAY, METERED
More Information on Dosage
STRIVERDI RESPIMAT family patents
193. Sumavel Dosepro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7901385 | ENDO OPERATIONS | Casing |
Jul, 2026
(1 year, 7 months from now) | |
| US7776007 | ENDO OPERATIONS | Device for readying a needle free injector for delivery |
Nov, 2026
(1 year, 11 months from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 26 November, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
SUMAVEL DOSEPRO family patents
194. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11753368 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 5 months from now) | |
| US10351517 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 5 months from now) | |
| US9604917 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 5 months from now) | |
| US8877806 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
195. Supprelin La patent expiration
SUPPRELIN LA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062652 | ENDO OPERATIONS | Compositions and methods for treating precocious puberty |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 03, 2014 |
Drugs and Companies using HISTRELIN ACETATE ingredient
Market Authorisation Date: 03 May, 2007
Treatment: Method of treatment of children with central precocious puberty
Dosage: IMPLANT
More Information on Dosage
SUPPRELIN LA family patents
196. Syfovre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056076 | APELLIS PHARMS | Method of treating age-related macular degeneration comprising administering a compstatin analog |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan
Dosage: SOLUTION
More Information on Dosage
SYFOVRE family patents
197. Symbicort patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7587988 | ASTRAZENECA | Inhaler device counter |
Apr, 2026
(1 year, 3 months from now) | |
|
US7587988 (Pediatric) | ASTRAZENECA | Inhaler device counter |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| New Patient Population(NPP) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| M(M-210) | Sep 11, 2020 |
| M(M-214) | Dec 20, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage
SYMBICORT family patents
198. Symdeko (copackaged) patent expiration
SYMDEKO (COPACKAGED)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(1 year, 6 months from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients age 6 years and older who have a r117h mutation in the cftr gene; Tezacaftor and ivacaftor for the treatment of cystic fibrosi...
Dosage: TABLET
More Information on Dosage
SYMDEKO (COPACKAGED) family patents
199. Symproic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536192 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(1 year, 9 months from now) | |
| USRE46375 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET
More Information on Dosage
SYMPROIC family patents
200. Symtuza patent expiration
SYMTUZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage
SYMTUZA family patents
201. Synribo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6987103 | TEVA PHARMS INTL | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2017 |
| Orphan Drug Exclusivity(ODE) | Oct 26, 2019 |
| Orphan Drug Exclusivity(ODE-32) | Oct 26, 2019 |
Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient
NCE-1 date: 26 October, 2016
Market Authorisation Date: 26 October, 2012
Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)
Dosage: POWDER
How can I launch a generic of SYNRIBO before it's drug patent expiration?
More Information on Dosage
SYNRIBO family patents
202. Tasigna patent expiration
TASIGNA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(1 year, 6 months from now) | |
| US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: CAPSULE
How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage
TASIGNA family patents
203. Tavalisse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8211889 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(1 year, 1 month from now) | |
| US7538108 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(1 year, 3 months from now) | |
| US7989448 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 5 months from now) | |
| US8163902 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266912 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(1 year, 1 month from now) | |
| USRE48898 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(1 year, 1 month from now) | |
| US9737554 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(1 year, 1 month from now) | |
| US8445485 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 5 months from now) | |
| US8912170 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 5 months from now) | |
| US9283238 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
Dosage: TABLET
How can I launch a generic of TAVALISSE before it's drug patent expiration?
More Information on Dosage
TAVALISSE family patents
204. Tekturna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617595 | NODEN PHARMA | Galenic formulations of organic compounds |
Feb, 2026
(1 year, 2 months from now) | |
|
US8617595 (Pediatric) | NODEN PHARMA | Galenic formulations of organic compounds |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Product(NP) | Nov 14, 2020 |
| Pediatric Exclusivity(PED) | May 14, 2021 |
Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 05 March, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of TEKTURNA before it's drug patent expiration?
More Information on Dosage
TEKTURNA family patents
205. Topicort patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8715624 | TARO | Stable liquid desoximethasone compositions with reduced oxidized impurity |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Apr 11, 2016 |
Drugs and Companies using DESOXIMETASONE ingredient
Market Authorisation Date: 11 April, 2013
Treatment: Treatment of plaque psoriasis in patients 18 years of age or older
Dosage: SPRAY
How can I launch a generic of TOPICORT before it's drug patent expiration?
More Information on Dosage
TOPICORT family patents
206. Torisel patent expiration
TORISEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(1 year, 1 month from now) | |
|
US8026276 (Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-91) | Apr 26, 2013 |
| M(M-92) | Jul 09, 2013 |
| Pediatric Exclusivity(PED) | Jan 09, 2014 |
| Orphan Drug Exclusivity(ODE) | May 30, 2014 |
| M(M-61) | May 30, 2015 |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage
TORISEL family patents
207. Tosymra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440631 | TONIX MEDS | Compositions for drug administration |
May, 2026
(1 year, 4 months from now) | |
| US9283280 | TONIX MEDS | Compositions for drug administration |
May, 2026
(1 year, 4 months from now) | |
| US8268791 | TONIX MEDS | Alkylglycoside compositions for drug administration |
May, 2026
(1 year, 4 months from now) | |
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY
More Information on Dosage
TOSYMRA family patents
208. Tracleer patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-607) | Aug 07, 2012 |
| New Product(NP) | Sep 05, 2020 |
| New Patient Population(NPP) | Sep 05, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 05, 2024 |
| ODE*(ODE*) | Sep 05, 2024 |
| Orphan Drug Exclusivity(ODE-161) | Sep 05, 2024 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 05 September, 2017
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
How can I launch a generic of TRACLEER before it's drug patent expiration?
More Information on Dosage
TRACLEER family patents
209. Tradjenta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
210. Treanda patent expiration
TREANDA's oppositions filed in EPO
TREANDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 25 days from now) | |
| US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 25 days from now) | |
| US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 25 days from now) | |
|
US8791270 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(1 year, 6 months from now) | |
|
US8895756 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(1 year, 6 months from now) | |
|
US8609863 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-580) | Oct 31, 2011 |
| New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
| Pediatric Exclusivity(PED) | May 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 31, 2015 |
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma
Dosage: POWDER; SOLUTION
How can I launch a generic of TREANDA before it's drug patent expiration?
More Information on Dosage
TREANDA family patents
211. Tresiba patent expiration
TRESIBA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TRESIBA family patents
212. Treximet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7332183 (Pediatric) | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Apr, 2026
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 14, 2018 |
| Pediatric Exclusivity(PED) | Nov 14, 2018 |
Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 14 May, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of TREXIMET before it's drug patent expiration?
More Information on Dosage
TREXIMET family patents
213. Tri-luma patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7915243 | GALDERMA LABS LP | Topical skin care composition |
Mar, 2026
(1 year, 3 months from now) | |
Drugs and Companies using FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN ingredient
Market Authorisation Date: 18 January, 2002
Treatment: NA
Dosage: CREAM
More Information on Dosage
TRI-LUMA family patents
214. Trijardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(1 year, 5 months from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
215. Trikafta (copackaged) patent expiration
TRIKAFTA (COPACKAGED)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(1 year, 6 months from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 08, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
| Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have a r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatment of cf in patients 6 years and older wh...
Dosage: GRANULES; TABLET
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
216. Trintellix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7144884 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Jun, 2026
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7144884 (Pediatric) | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Dec, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2018 |
| M(M-227) | May 02, 2021 |
| M(M-234) | Oct 19, 2021 |
| M(M-267) | Nov 13, 2023 |
| M(M-187) | Jan 22, 2024 |
| M(M-232) | Aug 23, 2026 |
| Pediatric Exclusivity(PED) | Feb 23, 2027 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
NCE-1 date: 23 February, 2026
Market Authorisation Date: 30 September, 2013
Treatment: Method of treating an affective disorder such as depression
Dosage: TABLET
How can I launch a generic of TRINTELLIX before it's drug patent expiration?
More Information on Dosage
TRINTELLIX family patents
217. Tygacil patent expiration
TYGACIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(1 year, 2 months from now) | |
| US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(1 year, 2 months from now) | |
| US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-586) | Mar 20, 2012 |
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER
More Information on Dosage
TYGACIL family patents
218. Uptravi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Treatment: Method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag
Dosage: TABLET; POWDER
How can I launch a generic of UPTRAVI before it's drug patent expiration?
More Information on Dosage
UPTRAVI family patents
219. Valchlor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501819 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(1 year, 2 months from now) | |
| US7838564 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(1 year, 2 months from now) | |
| US8501818 | HELSINN | Stabilized compositions of alkylating agents and methods of using same |
Mar, 2026
(1 year, 2 months from now) | |
| US8450375 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(1 year, 2 months from now) | |
| US9382191 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 23, 2020 |
| Orphan Drug Exclusivity(ODE-51) | Aug 23, 2020 |
Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy
Dosage: GEL
More Information on Dosage
VALCHLOR family patents
220. Valturna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168616 | NOVARTIS | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
Jul, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Sep 16, 2012 |
Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 16 September, 2009
Treatment: NA
Dosage: TABLET
More Information on Dosage
VALTURNA family patents
221. Veramyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8752543 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | |
| US8062264 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
VERAMYST family patents
222. Veregen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858662 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Oct, 2026
(1 year, 9 months from now) | |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Treatment: Treatment of genital warts
Dosage: OINTMENT
More Information on Dosage
VEREGEN family patents
223. Verkazia patent expiration
Can you believe VERKAZIA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11612658 | HARROW EYE | Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same |
Jan, 2026
(1 year, 1 month from now) | |
| US9956289 | HARROW EYE | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 1 month from now) | |
| US8524779 | HARROW EYE | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 1 month from now) | |
| US9220694 | HARROW EYE | Emulsion compositions containing cetalkonium chloride |
Jan, 2026
(1 year, 1 month from now) | |
| US7973081 | HARROW EYE | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 23, 2024 |
| Orphan Drug Exclusivity(ODE-358) | Jun 23, 2028 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 June, 2021
Treatment: For the treatment of vernal keratoconjunctivitis in children and adults
Dosage: EMULSION
More Information on Dosage
VERKAZIA family patents
224. Victoza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8114833 (Pediatric) | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| M(M-115) | Apr 06, 2015 |
| M(M-176) | Apr 22, 2019 |
| New Indication(I-750) | Aug 25, 2020 |
| New Patient Population(NPP) | Jun 17, 2022 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage
VICTOZA family patents
225. Vitekta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(1 year, 8 months from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(1 year, 10 months from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
Drugs and Companies using ELVITEGRAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: Treatment of hiv infection
Dosage: TABLET
More Information on Dosage
VITEKTA family patents
226. Vizimpro patent expiration
VIZIMPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603314 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(1 year, 1 month from now) | |
| US10596162 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2023 |
| Orphan Drug Exclusivity(ODE-206) | Sep 27, 2025 |
| Orphan Drug Exclusivity(ODE-213) | Sep 27, 2025 |
Drugs and Companies using DACOMITINIB ingredient
NCE-1 date: 27 September, 2022
Market Authorisation Date: 27 September, 2018
Treatment: Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion...
Dosage: TABLET
More Information on Dosage
VIZIMPRO family patents
227. Vocabria patent expiration
VOCABRIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(1 year, 4 months from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-273) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: TABLET
More Information on Dosage
VOCABRIA family patents
228. Vyxeos patent expiration
VYXEOS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518437 | CELATOR PHARMS | Lipid carrier compositions with enhanced blood stability |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 03, 2020 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
VYXEOS family patents
229. Wakix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8354430 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine |
Feb, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-846) | Oct 13, 2023 |
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2024 |
| Orphan Drug Exclusivity(ODE-255) | Aug 14, 2026 |
| New Patient Population(NPP) | Jun 21, 2027 |
| Orphan Drug Exclusivity(ODE-331) | Oct 13, 2027 |
| Orphan Drug Exclusivity(ODE-489) | Jun 21, 2031 |
Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient
NCE-1 date: 15 August, 2023
Market Authorisation Date: 14 August, 2019
Treatment: Method of treating cataplexy in patients with narcolepsy
Dosage: TABLET
More Information on Dosage
WAKIX family patents
230. Wegovy patent expiration
WEGOVY's oppositions filed in EPO
WEGOVY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Jun 04, 2024 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage
WEGOVY family patents
231. Xeglyze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7812163 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Oct, 2026
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION
More Information on Dosage
XEGLYZE family patents
232. Xifaxan patent expiration
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741904 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10703763 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 2 months from now) | |
| US8518949 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 2 months from now) | |
| US9271968 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 25 May, 2004
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
233. Xigduo Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 28 July, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage
XIGDUO XR family patents
234. Xiidra patent expiration
Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8084047 | BAUSCH AND LOMB INC | Compositions and methods for treatment of eye disorders |
May, 2026
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592450 | BAUSCH AND LOMB INC | Compositions and methods for treatment of eye disorders |
May, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage
XIIDRA family patents
235. Xtandi patent expiration
XTANDI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126941 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
May, 2026
(1 year, 4 months from now) | |
| US8183274 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
Aug, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 31, 2017 |
| New Indication(I-693) | Sep 10, 2017 |
| New Indication(I-786) | Jul 13, 2021 |
| New Indication(I-808) | Dec 16, 2022 |
| New Indication(I-926) | Nov 17, 2026 |
Drugs and Companies using ENZALUTAMIDE ingredient
Market Authorisation Date: 04 August, 2020
Treatment: Treatment of patients with non-metastatic castration-sensitive prostate cancer (nmcspc) with biochemical recurrence (bcr) at high risk for metastasis
Dosage: TABLET; CAPSULE
How can I launch a generic of XTANDI before it's drug patent expiration?
More Information on Dosage
XTANDI family patents
236. Xultophy 100/3.6 patent expiration
XULTOPHY 100/3.6's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 1 month from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 1 month from now) | |
|
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(1 year, 4 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 6 months from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 6 months from now) | |
|
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(1 year, 7 months from now) | |
|
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(1 year, 7 months from now) | |
|
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(1 year, 7 months from now) | |
| US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
| M(M-242) | Aug 08, 2022 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XULTOPHY 100/3.6 family patents
237. Xyosted (autoinjector) patent expiration
XYOSTED (AUTOINJECTOR)'s oppositions filed in EPO
Can you believe XYOSTED (AUTOINJECTOR) received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629959 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US11446441 | ANTARES PHARMA INC | Prefilled syringe injector |
Jan, 2026
(1 year, 1 month from now) | |
| US9533102 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US10478560 | ANTARES PHARMA INC | Prefilled syringe injector |
Jan, 2026
(1 year, 1 month from now) | |
| US8562564 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US9180259 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US8021335 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XYOSTED (AUTOINJECTOR) family patents
238. Zelboraf patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8143271 | HOFFMANN LA ROCHE | NA |
Jun, 2026
(1 year, 6 months from now) | |
| US7504509 | HOFFMANN LA ROCHE | Compounds and methods for development of Ret modulators |
Oct, 2026
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470818 | HOFFMANN LA ROCHE | NA |
Aug, 2026
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
| Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
| M(M-184) | Aug 31, 2019 |
| New Indication(I-757) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Treatment: Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test
Dosage: TABLET
More Information on Dosage
ZELBORAF family patents
239. Zelsuvmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8956658 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(1 year, 5 months from now) | |
| US8282967 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Treatment: NA
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents
240. Zetia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7612058 (Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 05, 2011 |
| M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Treatment: NA
Dosage: TABLET
How can I launch a generic of ZETIA before it's drug patent expiration?
More Information on Dosage
ZETIA family patents
241. Zolinza patent expiration
Can you believe ZOLINZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8093295 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
ZOLINZA family patents
242. Ztalmy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9029355 | MARINUS | Solid ganaxolone compositions and methods for the making and use thereof |
Nov, 2026
(1 year, 11 months from now) | |
| US7858609 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 11 months from now) | |
| US8318714 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 11 months from now) | |
| US8618087 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 11 months from now) | |
| US8022054 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 11 months from now) | |
| US8367651 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 11 months from now) | |
| US9056116 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2027 |
| Orphan Drug Exclusivity(ODE-395) | Jun 01, 2029 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: 01 June, 2026
Market Authorisation Date: 01 June, 2022
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older
Dosage: SUSPENSION
More Information on Dosage
ZTALMY family patents
243. Zunveyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9763953 | ALPHA COGNITION | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Dec, 2026
(1 year, 11 months from now) | |
Drugs and Companies using BENZGALANTAMINE GLUCONATE ingredient
Market Authorisation Date: 26 July, 2024
Treatment: Treatment of mild to moderate dementia of the alzheimer's type
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
ZUNVEYL family patents
244. Zurnai (autoinjector) patent expiration
ZURNAI (AUTOINJECTOR)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180259 | PURDUE PHARMA LP | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US9629959 | PURDUE PHARMA LP | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US8562564 | PURDUE PHARMA LP | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US11446441 | PURDUE PHARMA LP | Prefilled syringe injector |
Jan, 2026
(1 year, 1 month from now) | |
| US9533102 | PURDUE PHARMA LP | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | |
| US10478560 | PURDUE PHARMA LP | Prefilled syringe injector |
Jan, 2026
(1 year, 1 month from now) | |
| US8021335 | PURDUE PHARMA LP | Prefilled syringe jet injector |
Oct, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using NALMEFENE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 August, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ZURNAI (AUTOINJECTOR) family patents
245. Zykadia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7893074 | NOVARTIS | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2026
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
| M(M-199) | May 26, 2020 |
| Orphan Drug Exclusivity(ODE-66) | Apr 29, 2021 |
| Orphan Drug Exclusivity(ODE) | May 26, 2024 |
| ODE*(ODE*) | May 26, 2024 |
| Orphan Drug Exclusivity(ODE-145) | May 26, 2024 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 29 April, 2014
Treatment: NA
Dosage: TABLET
More Information on Dosage
ZYKADIA family patents
List of large molecules
1. List of Actemra large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8617550 | GENENTECH, INC. | Treatment of vasculitis with IL-6 antagonist |
Mar, 2026
(1 year, 2 months from now) |
Ingredients: TOCILIZUMAB
2. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10406226 | REGENERON PHARMACEUTICALS, INC. | Method of manufacturing VEGF antagonist fusion proteins |
Mar, 2026
(1 year, 3 months from now) |
Ingredients: AFLIBERCEPT
3. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9709575 | BIOGEN INC. | Methods and products for evaluating an immune response to a therapeutic protein |
Apr, 2026
(1 year, 3 months from now) | |
| US10705095 | BIOGEN INC. | Methods and products for evaluating an immune response to a therapeutic protein |
Apr, 2026
(1 year, 3 months from now) | |
| US8871449 | BIOGEN INC. | Methods and products for evaluating an immune response to a therapeutic protein |
Apr, 2026
(1 year, 3 months from now) |
Ingredients: NATALIZUMAB
4. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8808700 | ABBVIE INC. | Use of TNF alpha inhibitor for treatment of erosive polyarthritis |
May, 2026
(1 year, 4 months from now) |
Ingredients: ADALIMUMAB
5. List of Rituxan large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10654940 | GENENTECH, INC. | Method for treating joint damage |
Nov, 2026
(1 year, 10 months from now) | |
| US10450379 | GENENTECH, INC. | Method for treating joint damage |
Nov, 2026
(1 year, 10 months from now) |
Ingredients: RITUXIMAB
6. List of Prolia And Xgeva large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8460896 | AMGEN INC. | Host cells and culture methods |
Dec, 2026
(1 year, 11 months from now) | |
| US8247210 | AMGEN INC. | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
Dec, 2026
(1 year, 11 months from now) | |
| US8680248 | AMGEN INC. | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
Dec, 2026
(1 year, 11 months from now) |
Ingredients: DENOSUMAB